nodes	percent_of_prediction	percent_of_DWPC	metapath
Milnacipran—Parkinsonism—Fluorouracil—head and neck cancer	0.035	0.035	CcSEcCtD
Milnacipran—Supraventricular tachycardia—Docetaxel—head and neck cancer	0.0175	0.0175	CcSEcCtD
Milnacipran—Renal failure acute—Hydroxyurea—head and neck cancer	0.0174	0.0174	CcSEcCtD
Milnacipran—Angina pectoris—Vinblastine—head and neck cancer	0.0148	0.0148	CcSEcCtD
Milnacipran—Breast disorder—Hydroxyurea—head and neck cancer	0.0145	0.0145	CcSEcCtD
Milnacipran—Chest discomfort—Docetaxel—head and neck cancer	0.013	0.013	CcSEcCtD
Milnacipran—Dysuria—Hydroxyurea—head and neck cancer	0.013	0.013	CcSEcCtD
Milnacipran—Neutropenia—Hydroxyurea—head and neck cancer	0.013	0.013	CcSEcCtD
Milnacipran—Hypoaesthesia—Vinblastine—head and neck cancer	0.0121	0.0121	CcSEcCtD
Milnacipran—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.0117	0.0117	CcSEcCtD
Milnacipran—Blood pressure increased—Docetaxel—head and neck cancer	0.0115	0.0115	CcSEcCtD
Milnacipran—Hallucination—Hydroxyurea—head and neck cancer	0.011	0.011	CcSEcCtD
Milnacipran—Irritability—Fluorouracil—head and neck cancer	0.011	0.011	CcSEcCtD
Milnacipran—Dry skin—Fluorouracil—head and neck cancer	0.0106	0.0106	CcSEcCtD
Milnacipran—Angiopathy—Hydroxyurea—head and neck cancer	0.0101	0.0101	CcSEcCtD
Milnacipran—Chills—Hydroxyurea—head and neck cancer	0.00996	0.00996	CcSEcCtD
Milnacipran—Angina pectoris—Fluorouracil—head and neck cancer	0.00972	0.00972	CcSEcCtD
Milnacipran—Leukopenia—Vinblastine—head and neck cancer	0.00948	0.00948	CcSEcCtD
Milnacipran—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00928	0.00928	CcSEcCtD
Milnacipran—Convulsion—Vinblastine—head and neck cancer	0.00918	0.00918	CcSEcCtD
Milnacipran—Hypertension—Vinblastine—head and neck cancer	0.00915	0.00915	CcSEcCtD
Milnacipran—Hot flush—Docetaxel—head and neck cancer	0.00891	0.00891	CcSEcCtD
Milnacipran—Menopausal symptoms—Docetaxel—head and neck cancer	0.00883	0.00883	CcSEcCtD
Milnacipran—Urinary tract infection—Fluorouracil—head and neck cancer	0.00865	0.00865	CcSEcCtD
Milnacipran—Leukopenia—Hydroxyurea—head and neck cancer	0.00865	0.00865	CcSEcCtD
Milnacipran—Thrombocytopenia—Vinblastine—head and neck cancer	0.00847	0.00847	CcSEcCtD
Milnacipran—Convulsion—Hydroxyurea—head and neck cancer	0.00837	0.00837	CcSEcCtD
Milnacipran—Hyponatraemia—Docetaxel—head and neck cancer	0.00837	0.00837	CcSEcCtD
Milnacipran—Anorexia—Vinblastine—head and neck cancer	0.00824	0.00824	CcSEcCtD
Milnacipran—Migraine—Docetaxel—head and neck cancer	0.00821	0.00821	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00817	0.00817	CcSEcCtD
Milnacipran—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00795	0.00795	CcSEcCtD
Milnacipran—Infection—Hydroxyurea—head and neck cancer	0.00783	0.00783	CcSEcCtD
Milnacipran—Paraesthesia—Vinblastine—head and neck cancer	0.00777	0.00777	CcSEcCtD
Milnacipran—Nervous system disorder—Hydroxyurea—head and neck cancer	0.00773	0.00773	CcSEcCtD
Milnacipran—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.00772	0.00772	CcSEcCtD
Milnacipran—Liver function test abnormal—Docetaxel—head and neck cancer	0.0077	0.0077	CcSEcCtD
Milnacipran—Skin disorder—Hydroxyurea—head and neck cancer	0.00766	0.00766	CcSEcCtD
Milnacipran—Dry skin—Docetaxel—head and neck cancer	0.00764	0.00764	CcSEcCtD
Milnacipran—Breast disorder—Docetaxel—head and neck cancer	0.00753	0.00753	CcSEcCtD
Milnacipran—Anorexia—Hydroxyurea—head and neck cancer	0.00752	0.00752	CcSEcCtD
Milnacipran—Decreased appetite—Vinblastine—head and neck cancer	0.00752	0.00752	CcSEcCtD
Milnacipran—Constipation—Vinblastine—head and neck cancer	0.0074	0.0074	CcSEcCtD
Milnacipran—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00707	0.00707	CcSEcCtD
Milnacipran—Dyspnoea—Hydroxyurea—head and neck cancer	0.00703	0.00703	CcSEcCtD
Milnacipran—Angina pectoris—Docetaxel—head and neck cancer	0.00702	0.00702	CcSEcCtD
Milnacipran—Somnolence—Hydroxyurea—head and neck cancer	0.00701	0.00701	CcSEcCtD
Milnacipran—Dyspepsia—Hydroxyurea—head and neck cancer	0.00694	0.00694	CcSEcCtD
Milnacipran—Decreased appetite—Hydroxyurea—head and neck cancer	0.00686	0.00686	CcSEcCtD
Milnacipran—Abdominal pain—Vinblastine—head and neck cancer	0.00684	0.00684	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00681	0.00681	CcSEcCtD
Milnacipran—Fatigue—Hydroxyurea—head and neck cancer	0.0068	0.0068	CcSEcCtD
Milnacipran—Constipation—Hydroxyurea—head and neck cancer	0.00674	0.00674	CcSEcCtD
Milnacipran—Neutropenia—Docetaxel—head and neck cancer	0.00674	0.00674	CcSEcCtD
Milnacipran—Vision blurred—Fluorouracil—head and neck cancer	0.00656	0.00656	CcSEcCtD
Milnacipran—Weight decreased—Docetaxel—head and neck cancer	0.00652	0.00652	CcSEcCtD
Milnacipran—Hypersensitivity—Vinblastine—head and neck cancer	0.00637	0.00637	CcSEcCtD
Milnacipran—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.00637	0.00637	CcSEcCtD
Milnacipran—Body temperature increased—Hydroxyurea—head and neck cancer	0.00623	0.00623	CcSEcCtD
Milnacipran—Leukopenia—Fluorouracil—head and neck cancer	0.00623	0.00623	CcSEcCtD
Milnacipran—Asthenia—Vinblastine—head and neck cancer	0.0062	0.0062	CcSEcCtD
Milnacipran—Hepatobiliary disease—Docetaxel—head and neck cancer	0.00608	0.00608	CcSEcCtD
Milnacipran—Convulsion—Fluorouracil—head and neck cancer	0.00603	0.00603	CcSEcCtD
Milnacipran—Chest pain—Fluorouracil—head and neck cancer	0.00592	0.00592	CcSEcCtD
Milnacipran—Diarrhoea—Vinblastine—head and neck cancer	0.00592	0.00592	CcSEcCtD
Milnacipran—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00581	0.00581	CcSEcCtD
Milnacipran—Hepatitis—Docetaxel—head and neck cancer	0.00577	0.00577	CcSEcCtD
Milnacipran—Hypoaesthesia—Docetaxel—head and neck cancer	0.00574	0.00574	CcSEcCtD
Milnacipran—Dizziness—Vinblastine—head and neck cancer	0.00572	0.00572	CcSEcCtD
Milnacipran—Urinary tract disorder—Docetaxel—head and neck cancer	0.0057	0.0057	CcSEcCtD
Milnacipran—Oedema peripheral—Docetaxel—head and neck cancer	0.00568	0.00568	CcSEcCtD
Milnacipran—Connective tissue disorder—Docetaxel—head and neck cancer	0.00567	0.00567	CcSEcCtD
Milnacipran—Asthenia—Hydroxyurea—head and neck cancer	0.00566	0.00566	CcSEcCtD
Milnacipran—Urethral disorder—Docetaxel—head and neck cancer	0.00565	0.00565	CcSEcCtD
Milnacipran—Infection—Fluorouracil—head and neck cancer	0.00564	0.00564	CcSEcCtD
Milnacipran—Nervous system disorder—Fluorouracil—head and neck cancer	0.00557	0.00557	CcSEcCtD
Milnacipran—Thrombocytopenia—Fluorouracil—head and neck cancer	0.00556	0.00556	CcSEcCtD
Milnacipran—Tachycardia—Fluorouracil—head and neck cancer	0.00554	0.00554	CcSEcCtD
Milnacipran—Vomiting—Vinblastine—head and neck cancer	0.0055	0.0055	CcSEcCtD
Milnacipran—Erythema multiforme—Docetaxel—head and neck cancer	0.00545	0.00545	CcSEcCtD
Milnacipran—Headache—Vinblastine—head and neck cancer	0.00542	0.00542	CcSEcCtD
Milnacipran—Anorexia—Fluorouracil—head and neck cancer	0.00541	0.00541	CcSEcCtD
Milnacipran—Diarrhoea—Hydroxyurea—head and neck cancer	0.0054	0.0054	CcSEcCtD
Milnacipran—Eye disorder—Docetaxel—head and neck cancer	0.00539	0.00539	CcSEcCtD
Milnacipran—Flushing—Docetaxel—head and neck cancer	0.00535	0.00535	CcSEcCtD
Milnacipran—Cardiac disorder—Docetaxel—head and neck cancer	0.00535	0.00535	CcSEcCtD
Milnacipran—Hypotension—Fluorouracil—head and neck cancer	0.0053	0.0053	CcSEcCtD
Milnacipran—Angiopathy—Docetaxel—head and neck cancer	0.00523	0.00523	CcSEcCtD
Milnacipran—Dizziness—Hydroxyurea—head and neck cancer	0.00522	0.00522	CcSEcCtD
Milnacipran—Mediastinal disorder—Docetaxel—head and neck cancer	0.0052	0.0052	CcSEcCtD
Milnacipran—Chills—Docetaxel—head and neck cancer	0.00517	0.00517	CcSEcCtD
Milnacipran—Nausea—Vinblastine—head and neck cancer	0.00514	0.00514	CcSEcCtD
Milnacipran—Insomnia—Fluorouracil—head and neck cancer	0.00513	0.00513	CcSEcCtD
Milnacipran—Paraesthesia—Fluorouracil—head and neck cancer	0.0051	0.0051	CcSEcCtD
Milnacipran—Dyspnoea—Fluorouracil—head and neck cancer	0.00506	0.00506	CcSEcCtD
Milnacipran—Mental disorder—Docetaxel—head and neck cancer	0.00505	0.00505	CcSEcCtD
Milnacipran—Somnolence—Fluorouracil—head and neck cancer	0.00505	0.00505	CcSEcCtD
Milnacipran—Malnutrition—Docetaxel—head and neck cancer	0.00502	0.00502	CcSEcCtD
Milnacipran—Vomiting—Hydroxyurea—head and neck cancer	0.00501	0.00501	CcSEcCtD
Milnacipran—Dyspepsia—Fluorouracil—head and neck cancer	0.005	0.005	CcSEcCtD
Milnacipran—Rash—Hydroxyurea—head and neck cancer	0.00497	0.00497	CcSEcCtD
Milnacipran—Dermatitis—Hydroxyurea—head and neck cancer	0.00497	0.00497	CcSEcCtD
Milnacipran—Headache—Hydroxyurea—head and neck cancer	0.00494	0.00494	CcSEcCtD
Milnacipran—Decreased appetite—Fluorouracil—head and neck cancer	0.00493	0.00493	CcSEcCtD
Milnacipran—Dysgeusia—Docetaxel—head and neck cancer	0.00492	0.00492	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.0049	0.0049	CcSEcCtD
Milnacipran—Nausea—Hydroxyurea—head and neck cancer	0.00468	0.00468	CcSEcCtD
Milnacipran—Urticaria—Fluorouracil—head and neck cancer	0.00451	0.00451	CcSEcCtD
Milnacipran—Syncope—Docetaxel—head and neck cancer	0.0045	0.0045	CcSEcCtD
Milnacipran—Leukopenia—Docetaxel—head and neck cancer	0.00449	0.00449	CcSEcCtD
Milnacipran—Body temperature increased—Fluorouracil—head and neck cancer	0.00449	0.00449	CcSEcCtD
Milnacipran—Palpitations—Docetaxel—head and neck cancer	0.00444	0.00444	CcSEcCtD
Milnacipran—Loss of consciousness—Docetaxel—head and neck cancer	0.00441	0.00441	CcSEcCtD
Milnacipran—Convulsion—Docetaxel—head and neck cancer	0.00435	0.00435	CcSEcCtD
Milnacipran—Hypertension—Docetaxel—head and neck cancer	0.00433	0.00433	CcSEcCtD
Milnacipran—Chest pain—Docetaxel—head and neck cancer	0.00427	0.00427	CcSEcCtD
Milnacipran—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00424	0.00424	CcSEcCtD
Milnacipran—Hypersensitivity—Fluorouracil—head and neck cancer	0.00418	0.00418	CcSEcCtD
Milnacipran—Dry mouth—Docetaxel—head and neck cancer	0.00418	0.00418	CcSEcCtD
Milnacipran—Infection—Docetaxel—head and neck cancer	0.00407	0.00407	CcSEcCtD
Milnacipran—Shock—Docetaxel—head and neck cancer	0.00403	0.00403	CcSEcCtD
Milnacipran—Nervous system disorder—Docetaxel—head and neck cancer	0.00402	0.00402	CcSEcCtD
Milnacipran—Pruritus—Fluorouracil—head and neck cancer	0.00402	0.00402	CcSEcCtD
Milnacipran—Thrombocytopenia—Docetaxel—head and neck cancer	0.00401	0.00401	CcSEcCtD
Milnacipran—Tachycardia—Docetaxel—head and neck cancer	0.004	0.004	CcSEcCtD
Milnacipran—Skin disorder—Docetaxel—head and neck cancer	0.00398	0.00398	CcSEcCtD
Milnacipran—Anorexia—Docetaxel—head and neck cancer	0.00391	0.00391	CcSEcCtD
Milnacipran—Diarrhoea—Fluorouracil—head and neck cancer	0.00388	0.00388	CcSEcCtD
Milnacipran—Hypotension—Docetaxel—head and neck cancer	0.00383	0.00383	CcSEcCtD
Milnacipran—Dizziness—Fluorouracil—head and neck cancer	0.00375	0.00375	CcSEcCtD
Milnacipran—Insomnia—Docetaxel—head and neck cancer	0.00371	0.00371	CcSEcCtD
Milnacipran—Paraesthesia—Docetaxel—head and neck cancer	0.00368	0.00368	CcSEcCtD
Milnacipran—Dyspnoea—Docetaxel—head and neck cancer	0.00365	0.00365	CcSEcCtD
Milnacipran—Somnolence—Docetaxel—head and neck cancer	0.00364	0.00364	CcSEcCtD
Milnacipran—Vomiting—Fluorouracil—head and neck cancer	0.00361	0.00361	CcSEcCtD
Milnacipran—Dyspepsia—Docetaxel—head and neck cancer	0.00361	0.00361	CcSEcCtD
Milnacipran—Rash—Fluorouracil—head and neck cancer	0.00358	0.00358	CcSEcCtD
Milnacipran—Dermatitis—Fluorouracil—head and neck cancer	0.00358	0.00358	CcSEcCtD
Milnacipran—Decreased appetite—Docetaxel—head and neck cancer	0.00356	0.00356	CcSEcCtD
Milnacipran—Headache—Fluorouracil—head and neck cancer	0.00356	0.00356	CcSEcCtD
Milnacipran—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00354	0.00354	CcSEcCtD
Milnacipran—Fatigue—Docetaxel—head and neck cancer	0.00353	0.00353	CcSEcCtD
Milnacipran—Constipation—Docetaxel—head and neck cancer	0.0035	0.0035	CcSEcCtD
Milnacipran—Nausea—Fluorouracil—head and neck cancer	0.00337	0.00337	CcSEcCtD
Milnacipran—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00335	0.00335	CcSEcCtD
Milnacipran—Abdominal pain—Docetaxel—head and neck cancer	0.00324	0.00324	CcSEcCtD
Milnacipran—Body temperature increased—Docetaxel—head and neck cancer	0.00324	0.00324	CcSEcCtD
Milnacipran—Hypersensitivity—Docetaxel—head and neck cancer	0.00302	0.00302	CcSEcCtD
Milnacipran—Asthenia—Docetaxel—head and neck cancer	0.00294	0.00294	CcSEcCtD
Milnacipran—Pruritus—Docetaxel—head and neck cancer	0.0029	0.0029	CcSEcCtD
Milnacipran—Diarrhoea—Docetaxel—head and neck cancer	0.0028	0.0028	CcSEcCtD
Milnacipran—Dizziness—Docetaxel—head and neck cancer	0.00271	0.00271	CcSEcCtD
Milnacipran—Vomiting—Docetaxel—head and neck cancer	0.00261	0.00261	CcSEcCtD
Milnacipran—Rash—Docetaxel—head and neck cancer	0.00258	0.00258	CcSEcCtD
Milnacipran—Dermatitis—Docetaxel—head and neck cancer	0.00258	0.00258	CcSEcCtD
Milnacipran—Headache—Docetaxel—head and neck cancer	0.00257	0.00257	CcSEcCtD
Milnacipran—Nausea—Docetaxel—head and neck cancer	0.00243	0.00243	CcSEcCtD
